The Angelini Lumira Biosciences Fund will invest in early-stage companies in Canada and the US.
Angelini Pharma, part of the privately-owned Angelini holding company based in Italy, has set up its corporate venturing group with an initial $35m.
The Angelini Lumira Biosciences Fund (ALBF) will be managed by Lumira Ventures, a Canada-based life sciences-focused venture capital firm. Angelini Pharma has also committed $5m as a limited partner in Lumira Ventures IV, a $220m life sciences fund, announced last month.
ALBF will invest in early-stage companies in Canada and the US that are developing pharmaceutical therapies for central nervous system…
